News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
858,067 Results
Type
Article (78357)
Company Profile (724)
Press Release (778957)
Multimedia
Podcasts (228)
Webinars (35)
Section
Business (229803)
Career Advice (3815)
Deals (39614)
Drug Delivery (175)
Drug Development (90359)
Employer Resources (207)
FDA (18351)
Job Trends (17323)
News (392071)
Policy (39251)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (2)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (4)
2027 Genetown Standard (3)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (5)
Academia (3048)
Academic (2)
Accelerated approval (54)
Adcomms (40)
Allergies (187)
Alliances (56470)
ALS (227)
Alzheimer's disease (1952)
Antibody-drug conjugate (ADC) (525)
Approvals (18665)
Artificial intelligence (803)
Autoimmune disease (338)
Automation (60)
Bankruptcy (405)
Best Places to Work (12635)
BIOSECURE Act (23)
Biosimilars (242)
Biotechnology (441)
Bladder cancer (207)
Brain cancer (83)
Breast cancer (813)
Cancer (6314)
Cardiovascular disease (542)
Career advice (3283)
Career pathing (51)
CAR-T (369)
CDC (76)
Celiac Disease (3)
Cell therapy (1024)
Cervical cancer (51)
Clinical research (77676)
Collaboration (2304)
Company closure (8)
Compensation (1461)
Complete response letters (103)
COVID-19 (3035)
CRISPR (120)
C-suite (1240)
Cystic fibrosis (166)
Data (8335)
Decentralized trials (3)
Denatured (87)
Depression (188)
Dermatology (94)
Diabetes (643)
Diagnostics (7538)
Digital health (61)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (388)
Drug pricing (244)
Drug shortages (39)
Duchenne muscular dystrophy (310)
Earnings (100372)
Editorial (78)
Employer branding (25)
Employer resources (174)
Events (137273)
Executive appointments (1173)
FDA (22296)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (36)
Funding (1875)
Gene editing (266)
Generative AI (79)
Gene therapy (834)
GLP-1 (1255)
Government (5525)
Grass and pollen (8)
Guidances (415)
Healthcare (21149)
HIV (90)
Huntington's disease (62)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (105)
Immunology and inflammation (350)
Immuno-oncology (107)
Indications (197)
Infectious disease (3418)
Inflammatory bowel disease (240)
Inflation Reduction Act (17)
Influenza (147)
Intellectual property (306)
Interviews (749)
IPO (17921)
IRA (61)
Job creations (5052)
Job search strategy (2643)
JPM (73)
Kidney cancer (21)
Labor market (115)
Layoffs (678)
Leadership (52)
Legal (10017)
Liver cancer (109)
Longevity (35)
Lung cancer (832)
Lymphoma (445)
Machine learning (64)
Management (66)
Manufacturing (1170)
MASH (219)
Medical device (15226)
Medtech (15364)
Mergers & acquisitions (22967)
Metabolic disorders (1726)
mRNA (258)
Multiple sclerosis (201)
NASH (24)
Neurodegenerative disease (486)
Neuropsychiatric disorders (125)
Neuroscience (3633)
Neurotech (1)
NextGen: Class of 2026 (7669)
Non-profit (5139)
Now hiring (79)
Obesity (831)
Opinion (370)
Ovarian cancer (237)
Pain (280)
Pancreatic cancer (326)
Parkinson's disease (400)
Partnered (37)
Patents (633)
Patient recruitment (720)
Peanut (67)
People (66967)
Pharmaceutical (129)
Pharmacy benefit managers (36)
Phase 1 (24032)
Phase 2 (33868)
Phase 3 (25480)
Pipeline (9277)
Policy (393)
Postmarket research (3308)
Preclinical (10656)
Press Release (72)
Prostate cancer (328)
Psychedelics (68)
Radiopharmaceuticals (361)
Rare diseases (1222)
Real estate (7280)
Recruiting (81)
Regulatory (29633)
Reports (78)
Research institute (2760)
Resumes & cover letters (593)
Rett syndrome (40)
RNA editing (28)
RSV (98)
Schizophrenia (193)
Series A (317)
Series B (229)
Service/supplier (26)
Sickle cell disease (122)
Special edition (32)
Spinal muscular atrophy (188)
Sponsored (55)
Startups (4283)
State (2)
Stomach cancer (21)
Supply chain (143)
Tariffs (104)
The Weekly (138)
Vaccines (1285)
Venture capital (127)
Weight loss (572)
Women's health (135)
Worklife (24)
Date
Today (209)
Last 7 days (629)
Last 30 days (3719)
Last 365 days (32791)
2026 (14467)
2025 (32699)
2024 (37914)
2023 (42563)
2022 (53927)
2021 (58719)
2020 (57662)
2019 (51314)
2018 (39097)
2017 (36913)
2016 (37886)
2015 (43902)
2014 (38728)
2013 (34881)
2012 (36713)
2011 (36809)
2010 (36472)
Location
Africa (1233)
Alabama (102)
Alaska (7)
Arizona (377)
Arkansas (16)
Asia (50880)
Australia (8732)
California (14041)
Canada (3923)
China (1492)
Colorado (603)
Connecticut (617)
Delaware (430)
Europe (116183)
Florida (2079)
Georgia (460)
Hawaii (4)
Idaho (68)
Illinois (1178)
India (99)
Indiana (649)
Iowa (25)
Japan (569)
Kansas (141)
Kentucky (56)
Louisiana (50)
Maine (89)
Maryland (1707)
Massachusetts (10243)
Michigan (414)
Minnesota (780)
Mississippi (7)
Missouri (162)
Montana (37)
Nebraska (30)
Nevada (151)
New Hampshire (92)
New Jersey (3725)
New Mexico (34)
New York (3676)
North Carolina (1893)
North Dakota (11)
Northern California (6964)
Ohio (434)
Oklahoma (26)
Oregon (53)
Pennsylvania (2782)
Puerto Rico (30)
Rhode Island (53)
South America (1595)
South Carolina (88)
South Dakota (2)
Southern California (5502)
Tennessee (222)
Texas (2260)
United States (50143)
Utah (421)
Vermont (1)
Virginia (357)
Washington D.C. (88)
Washington State (1153)
West Virginia (4)
Wisconsin (155)
Wyoming (2)
858,067 Results for "boehringer ingelheim pharma gmbh and co kg".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.
April 28, 2026
·
2 min read
·
Heather McKenzie
Press Releases
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
May 22, 2026
·
14 min read
Deals
Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+
While Boehringer Ingelheim hasn’t yet revealed what diseases it will go after, Sitryx’s oral drug candidate could potentially be disease-modifying for a variety of autoimmune and inflammatory conditions.
February 26, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Zealand Pharma announces Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
April 28, 2026
·
19 min read
Press Releases
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
April 13, 2026
·
4 min read
Press Releases
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
April 9, 2026
·
8 min read
Press Releases
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter
April 20, 2026
·
4 min read
Inflammatory bowel disease
Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere
The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.
January 27, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
April 28, 2026
·
14 min read
Press Releases
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
May 12, 2026
·
3 min read
1 of 85,807
Next
